Slide 1: When You Point
WHEN YOU WE POINT 7 8 Ph de eh eee ra 7" © 2026 CLEARPOINT NEURO 1
Slide 2: Disclaimer
DISCLAIMER Statements in this presentation and discussion concerning ClearPoint Neuro’s (the “Compan ) plans, looking statements within the context of the federal securities laws. Statements regarding th company's future ‘events, performance; the continued development, anticipated ‘shaun and potenti
Slide 3: Our Company: Precise Navigation to the Brain and Spine
Biologics and Drug Delivery Neuro Navigation Ablation Therapy and Robotics* and Access “Robotic product is in development phase. Commercialization is subject to successful development, testing, and applicable regulatory clearance Neurocritical Management CLEARPOINT OUR COMPANY We Enable Delivery of
Slide 4: The Future of Neuro Biologics and Drug Delivery is Here Today
Our Company The Future of Neuro Biologics and Drug Delivery is Here Today ~ More than 30 Million people in the U.S. alone Neurological diseases cost Americans nearly are estimated to suffer from ; $800 Billion annually. To reduce these costs, we must severe and debilitating neurological disorders. i
Slide 5: 60+ Active Pharma Partners and FDA Expedited Review
Our Company The Future of Neuro Biologics and Drug Delivery is Here Today ec0oe Of those 30 million patients, 2.1 million in the U.S. alone have ClearPoint Neuro has 60+ Active Pharma Partners, with 10+ disorders where a ClearPoint BioPharma Partner has already programs accepted for FDA expedited re
Slide 6: Our 4-Phase Strategy Positions ClearPoint for Decades of Growth
Our Company Our 4-Phase Strategy Positions ClearPoint for Decades of Growth 2026+ 2026+ 2020 - 2025 2010 - 2019 rin 4 | ESSENTIAL. fs: EVERYWHERE. Leg, 3 | FAST. FORWARD. BUILD A NEW $10B MARKET LONGSIDE OUR 60+ FUNDED. A LEVERAGE OUR EXISTING BIOPHARMA PARTNERS AND 1 | DESIGN. 2 | FOUNDATION. PORTF
Slide 7: Design. Discovery. Years in the Making
Design. Discovery. This Unique ClearPoint Ecosystem Has Been Years in the Making SmartFlow Neuro Cannula IRRAflow Active Fluid Exchange System (c . i. SmartFr XG learPoint Neuro embraced the unmet need in neuro martFrame biologics and drug delivery and has invested more than $200m over the past 15 y
Slide 8: Installed Base of More than 150 Active Global Centers
onze Funded. Foundation. 3° | Our Installed Base Has Grown to More than 150 Active Global Centers f Over 170 employees worldwide focused exclusively on Neuro @, @ ® @ oO @ oe 2 @ fo} @ @&, © es @ Active ClearPoint Installation (Additional Sites in Asia, EMEA, LATAM) © 2026 CLEARPOINT NEURO | 8
Slide 9: ~50% of Top Ranked Neurosurgery Programs Use ClearPoint
Funded. Foundation. ~50% of the Top Ranked Neurosurgery Programs use ClearPoint Technology US News & World Report Best Neurology/Neurosurgery Hospitals 2025-2026 are recognized for excelling in the treatment of complex, high-risk neurological specialty cases. Evaluation Criteria 45% Outcomes 35% Str
Slide 10: Stress-Tested QMS and Operations
Funded. Foundation. Stress-Tested QMS and Operations We have invested in our Research & Development, Quality and Manufacturing infrastructure to build confidence for both hospitals and biopharma partners We bring medical device expertise and regulatory combination product acumen to pharmaceutical co
Slide 11: Growth Continues While We Prepare for Commercial Drug Approvals
Funded. Foundation. Growth Continues Today While We Prepare for Commercial Drug Approvals HEADQUARTERS R&D, MANUFACTURING ADVANCED RESEARCH LABORATORIES Solana Beach, CA Carlsbad, CA Torrey Pines, CA $52-$56 (est) 2025 REVENUE GROSS MARGIN (A) (AB) $37.0m 61% PATENTS CASH & ISSUED CASH EQUIVALENTS (
Slide 12: Experienced Leadership in Place
Funded. Foundation. Experienced Leadership in Place EAECUTIVE LEADS Salle PS eu) Proven industry operators with decades of experience in medical devices, biopharmaceuticals, and clinical research. @ ) Joe Burnett Danilo D'Alessandro Jeremy Stigall Mazin Sabra Paul Larson, MD Ellisa Cholapranee Presi
Slide 13: Our 4-Pillar Growth Strategy
Fast. Forward. Our 4-Pillar Growth Strategy Collective $1.0B Existing Market Opportunity Today FAST. Anil] FORWARD. Our Fast. Forward. 4-Pillar Growth Strategy is to Win 20% of an Existing $1.0B Global Market Opportunity, Generate $200m in Annual Revenue, and to Achieve Cash Breakeven and Profitabil
Slide 14: Pillar 1: Pre-Commercial Biologics & Drug Delivery
Fast. Forward. °3s° | Pillar 1: Pre-Commercial Biologics & Drug Delivery 3. CLEARPOINT ADVANCED LABORATORIES. $ 3 00m + Existing Pre-Commercial ClearPoint Neuro currently offers a boutique, neuro-focused CRO complete with Biologics & device co-development services, pre-clinical testing capabilities,
Slide 15: Pillar 2: Neuro Navigation & Robotics
Fast. Forward. Pillar 2: Neuro Navigation & Robotics ClearPoint will provide unmatched flexibility by having a single pre-planning software offering several workflows deployed via either MRI, iCT and eventually Robotics. This strategy balances the consistency of delivery that biopharma partners desi
Slide 16: Pillar 3: Laser Therapy & Access
Fast. Forward. Pillar 3: Laser Therapy & Access ClearPoint Prism is a mobile laser therapy system featuring innovative non-cooled applicator technology that simplifies setup, reduces power and potentially ablation time, and enables efficient workflows. Surgeons can capitalize on workflow efficiency
Slide 17: Pillar 4: Neurocritical Management
Fast. Forward. Pillar 4: Neurocritical Management IRRAflow Neurocritical Care ClearPoint’s recent acquisition of IRRAS expands the portfolio with a unique and & Active CSF disruptive solution for neurocritical care and intracranial fluid management. Stans IRRAflow enables active irrigation and contr
Slide 18: Continued Investment in 4-Pillar Product Pipeline
Fast. Forward. Clear and Continued Investment in ClearPoint’s 4-Pillar Product Pipeline 1H 2026 2H 2026 1H2027, «} = 2H2027——} 2028+ 1 PET/SPECT Imaging Live : * Bioanalytic Lab Active » Translational Models for Radiolabeling Active t « Pathology Lab Active tumor, stroke and spinal Histopathology Ac
Slide 19: Win 20% of an Existing $1.0B Global Market Opportunity
Our Fast. Forward. 4-Pillar Growth Strategy is to Win 20% of an Existing $1.0B Global Market Opportunity, Generate $200m in Annual Revenue, and to Achieve Cash Breakeven and MEUHOLSHIMEAL CARE 5 one. < & ACTIVE CSF EXCHANGE Profitability Along the Way xpand Existing Portfolio Into Multiple New Indic
Slide 20: Essential. Everywhere.
Essential. Everywhere. ESSENTIAL. EVERYWHERE. f » It starts by being unique. Our Essential. Everywhere. Strategy | is to build a new market from the ground up where our unique ecosystem plays an essential role and enables 20,000 annual Cell & Gene Therapy procedures. “2: CLEARPOINT ADVANCED LABORATO
Slide 21: Our Unique Ecosystem Essential for Cell and Gene Therapy
Essential. Everywhere. Our Unique Ecosystem Will Play An Essential Role for Cell and Gene Therapy Bs S if pe || = 44 , — = A.l. Derived Patient Therapy and Patient Comprehensive Flexible Options for Multiple Biologic Confirmatory and Tissue Specific Specific Biophysics Pre-Planning Surgeon Selected
Slide 22: 60+ Active Pharma Partners, 25+ Active Clinical Trials
Indication Essential. Everywhere. ClearPoint Neuro Has 60+ Active Pharma Partners, 25+ Active Clinical Trials Preclinical Phase 1/2 Phase 3 Commercialization Parkinson's Disease Epilepsy Dementias Huntington’s Gliomas Rare Genetic Neuromuscular Stroke ..and more than 15 additional programs that are
Slide 23: 10+ Programs Under FDA Expedited Review and Enrolling
Essential. Everywhere. Indication Preclinical Phase 1/2 Phase 3 * | 10+ Programs Are Already Under FDA Expedited Review and Enrolling Commercialization Parkinson's (BlueRock) - BRT-DAO1. Parkinson's (AskBio) - AB-1005 Parkinson's (Kenai) - RNDP-O01. Parkinson's (Aspen) - ANPDOO1 Parkinson's - (Undis
Slide 24: Building Surgical Experience and Capacity for Drug Commercialization
Essential. Everywhere. Building Surgical Experience and Capacity to Prepare for Drug Commercialization nea Experienced CLPT Navigation exbiingilay Site and Participant in NevipeDSS Active CGT Trial © 2026 CLEARPOINT NEURO | 24
Slide 25: Essential. Everywhere. Strategy Expands to 5-Pillar Growth Strategy
Our Essential. Everywhere. Strategy Expands Our Vision into a 5-Pillar Growth Strategy Which Will Include Commercial Drug Delivery and Highlights Our Path to Achieving $500m in Revenue Segui Sein RUSE ENS Products DA Expedited Review across 8 Indications | NEUROCRITICAL CARE & ACTIVE CSF EXCHANGE 1g
Slide 26: Our 4-Phase Strategy Positions ClearPoint for Decades of Growth
Our Company Our 4-Phase Strategy Positions ClearPoint for Decades of Growth 2026+ 2026+ 2020 - 2025 2010 - 2019 rin 4 | ESSENTIAL. fs: EVERYWHERE. Leg, 3 | FAST. FORWARD. BUILD A NEW $10B MARKET LONGSIDE OUR 60+ FUNDED. A LEVERAGE OUR EXISTING BIOPHARMA PARTNERS AND 1 | DESIGN. 2 | FOUNDATION. PORTF